Our Steering Committee
Dr. Mark Swain
Dr. Giada Sebastiani
Dr. Giada Sebastiani
University of Calgary
Dr. Mark Swain is Professor of Medicine and Head of the Division of Gastroenterology and Hepatology at the University of Calgary, Alberta, Canada. He currently holds the Cal Wenzel Family Foundation Chair in Hepatology. Dr. Swain is a clinician-scientist with a basic science research interest focused on how liver dise
University of Calgary
Dr. Mark Swain is Professor of Medicine and Head of the Division of Gastroenterology and Hepatology at the University of Calgary, Alberta, Canada. He currently holds the Cal Wenzel Family Foundation Chair in Hepatology. Dr. Swain is a clinician-scientist with a basic science research interest focused on how liver diseases causes symptoms such as fatigue. His clinical interests are focused in the areas of quality improvement and wait time reduction strategies, and his clinical research interests involve studying fatty liver disease (NAFLD), primary biliary cirrhosis, autoimmune hepatitis and eradicating hepatitis C.
Dr. Giada Sebastiani
Dr. Giada Sebastiani
Dr. Giada Sebastiani
McGill University
Associate Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University
Dr. Sebastiani's research focuses on screening for liver fibrosis and fatty liver of at-risk populations, including HIV+ patients, patients with diabetes and obesity, women with polycystic ovary syndrome, and patients w
McGill University
Associate Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University
Dr. Sebastiani's research focuses on screening for liver fibrosis and fatty liver of at-risk populations, including HIV+ patients, patients with diabetes and obesity, women with polycystic ovary syndrome, and patients with inflammatory bowel syndrome. To conduct these studies, I employ serum fibrosis biomarkers and a non-invasive machine, which is ultrasound-based, named Fibroscan. I am also site investigator of multiple global clinical trials for antifibrotic compounds in NASH.
Dr. Alnoor Ramji
Dr. Giada Sebastiani
Dr. Alnoor Ramji
University of British Columbia
Dr. Alnoor Ramji is an Adjunct Clinician Scientist at BCCDC. In addition, he is a Clinical Associate Professor at UBC, practicing at the St. Paul's hospital site.
Dr. Ramji's area of clinical and research interest includes viral hepatitis and NASH. His center is involved in investigator-initiated studies, an
University of British Columbia
Dr. Alnoor Ramji is an Adjunct Clinician Scientist at BCCDC. In addition, he is a Clinical Associate Professor at UBC, practicing at the St. Paul's hospital site.
Dr. Ramji's area of clinical and research interest includes viral hepatitis and NASH. His center is involved in investigator-initiated studies, and Clinical Studies in phase IIa to phase IV in Hepatitis B, C and NASH. Other research interests include identification and linkage to care of persons with liver disease, and implementation science of models of care to assist with this process.
Dr. Keyur Patel
Dr. Giada Sebastiani
Dr. Alnoor Ramji
University of Toronto
Dr. Alnoor Ramji is an Adjunct Clinician Scientist at BCCDC. In addition, he is a Clinical Associate Professor at UBC, practicing at the St. Paul's hospital site.
Dr. Patel is a leading researcher in clinical and translational research relating to host metabolic risk factors and mechanisms of fibrosis in viral hepatiti
University of Toronto
Dr. Alnoor Ramji is an Adjunct Clinician Scientist at BCCDC. In addition, he is a Clinical Associate Professor at UBC, practicing at the St. Paul's hospital site.
Dr. Patel is a leading researcher in clinical and translational research relating to host metabolic risk factors and mechanisms of fibrosis in viral hepatitis, along with the development of non-invasive markers of fibrosis, and the incorporation of functional genomic tools in the development of biomarkers of disease progression.